TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6363935

Group type: EXPERIMENTAL
Intervention: 4.8 million units of aqueous procaine penicillin plus 1 g of probenecid
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: nine tablets of trimethoprim‐sulfamethoxazole daily for three days
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: 500 mg of tetracycline four times a day for five days
Number of subjects: 539
Study: 30625176

Group type: EXPERIMENTAL
Intervention: Case management intervention including training for healthcare assistants, information and quality circles for general practitioners, and 24 months of case management.
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Intervention group (case management).
Number of subjects: 736
Study: 29455372

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (G1 HP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (G2 CP)
Number of subjects: 50
Study: 27593420

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (n=36) using MyFitnessPal and Fitbit with 12 coaching calls over 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (n=18) with U.S. Dietary Guidelines and two brief calls
Number of subjects: 54
Study: 24821894

Group type: EXPERIMENTAL
Intervention: Performance Facilitation (PF)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Local Learning Collaboratives (LLCs)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Performance Facilitation + Local Learning Collaboratives (PF + LLC)
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Control (Performance Feedback + Academic Detailing)
Number of subjects: 1016
Study: 22215361

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study: 20134319

Group type: EXPERIMENTAL
Intervention: Percutaneous thrombectomy (PT) plus percutaneous coronary intervention (PCI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 104
Study: 18701236

Group type: EXPERIMENTAL
Intervention: NAP SACC intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (delayed-intervention)
Number of subjects: 114
Study: 16021438

Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg o.d.
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg o.d.
Number of subjects: 174
Study: 12964115

Group type: EXPERIMENTAL
Intervention: Elevated levels of quinolinic acid (QA) in cerebrospinal fluid (CSF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elevated levels of picolinic acid (PA) in cerebrospinal fluid (CSF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Increased QArcolon;KA ratio
Number of subjects: 100

Group type: COMPARATOR
Intervention: Higher concentrations of kynurenic acid (KA) in Malawian children with malaria compared to Vietnamese adults with malaria
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elevated levels of kynurenic acid (KA) in children with CM
Number of subjects: 100
Study: 10981241

Group type: EXPERIMENTAL
Intervention: Apothecon warfarin
Number of subjects: 113

Group type: COMPARATOR
Intervention: DuPont warfarin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Apothecon warfarin and DuPont warfarin
Number of subjects: 113
Study: 8834418

Group type: EXPERIMENTAL
Intervention: 15 mg oral test dose of haloperidol (HPDL) followed by maintenance doses of 2, 5 to 8, or 10 to 15 mg twice daily for 5 days to achieve low (< 5 ng/ml), medium (10-18 ng/ml), or high (> 25 ng/ml) Css range.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: C24h prediction formula for maintenance dose of HPDL.
Number of subjects: 92
Study: 1600051

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate foam (Proctocort) administered rectally
Number of subjects: 0
Study: 4017421

Group type: EXPERIMENTAL
Intervention: Losulazine (10 to 30 mg b.i.d.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Losulazine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Losulazine and Placebo
Number of subjects: 32
Study: 31262343

Group type: EXPERIMENTAL
Intervention: Repetitive Sensory Stimulation (RSS) for 45 minutes daily plus usual care for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care (UC) alone for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RSS
Number of subjects: 40
Study: 29935486

Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen (800 mg every 6 hours for 24 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous acetaminophen (1 g every 6 hours for 24 hours)
Number of subjects: 80
Study: 27863809

Group type: EXPERIMENTAL
Intervention: 75 mg LMTM twice a day
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: 125 mg LMTM twice a day
Number of subjects: 891

Group type: COMPARATOR
Intervention: Control (4 mg LMTM twice a day)
Number of subjects: 891
Study: 25003166

Group type: EXPERIMENTAL
Intervention: Social exclusion (Cyberball paradigm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inclusion (Cyberball paradigm)
Number of subjects: 0
Study: 20708391

Group type: EXPERIMENTAL
Intervention: EPA supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20367560

Group type: EXPERIMENTAL
Intervention: Home-based blood pressure measurement protocol (n=89)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Ordinary office-based hypertension treatment protocol (n=68)
Number of subjects: 157
Study: 18477123

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Number of subjects: 0
Study: 15892410

Group type: EXPERIMENTAL
Intervention: Sevoflurane (end‐tidal concentration 2%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study: 12699301

Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 10626559

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 3 IU/m2/day (1 mg/m2/day) (n = 35)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (n = 19)
Number of subjects: 54
Study: 8665546

Group type: EXPERIMENTAL
Intervention: Tolcapone (50-800 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2119935

Group type: EXPERIMENTAL
Intervention: Modified amino acids (MAA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard amino acids (SAA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (MAA and SAA)
Number of subjects: 20
Study: 7002480

Group type: EXPERIMENTAL
Intervention: 1200 mg tolmetin sodium daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 75 mg indomethacin daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29742904

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) treatment modules ordered according to pretreatment strengths
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unified Protocol (UP) treatment modules ordered according to pretreatment weaknesses
Number of subjects: 18
Study: 28846537

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pentax AirWay Scope
Number of subjects: 108

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 108

Group type: COMPARATOR
Intervention: GlideScope and Pentax compared to Macintosh
Number of subjects: 108
Study: 26719805

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT) in COPD patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: No long-term oxygen therapy (no LTOT) in COPD patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with interstitial lung disease (ILD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 32
Study: 24645324

Group type: EXPERIMENTAL
Intervention: early, enough methylprednisone combined with immunoglobulin
Number of subjects: 568

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 568
Study: 21499747

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (in patients with pericranial muscle tenderness)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (in patients with pericranial muscle tenderness)
Number of subjects: 68
Study: 18718654

Group type: EXPERIMENTAL
Intervention: Triceram-cpTi
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Super Porcelain Ti-22-cpTi
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vita Omega 900-Au-Pd alloy (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Vita Titankeramik-cpTi
Number of subjects: 96
Study: 16500361

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12957222

Group type: EXPERIMENTAL
Intervention: Isradipine (10 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) + Isradipine (10 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isradipine (10 mg) + Naltrexone (50 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10996336

Group type: EXPERIMENTAL
Intervention: Patients with PAD
Number of subjects: 42

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 42
Study: 9278834

Group type: EXPERIMENTAL
Intervention: 25 micrograms neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 micrograms neostigmine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 micrograms neostigmine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (15 mg hyperbaric bupivacaine + saline)
Number of subjects: 60
Study: 7761013

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchangers (HMEs)
Number of subjects: 28
Study: 2527542

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg once a day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indomethacin plus placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cilazapril plus placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 20
Study: 921245

Group type: EXPERIMENTAL
Intervention: Ribavirin (1,000 mg/day in four divided doses)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 29
Study: 30658942

Group type: EXPERIMENTAL
Intervention: Asymmetric split-dose regimen (25% on the day of colonoscopy and 75% the day before)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Symmetric split-dose regimen (standard split-dose)
Number of subjects: 161
Study: 26471240

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy session
Number of subjects: 30
Study: 25477199

Group type: EXPERIMENTAL
Intervention: Regular low-level alcohol consumption
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-users of alcohol
Number of subjects: 29
Study: 24642116

Group type: EXPERIMENTAL
Intervention: Point-of-care lactate measurement (fingerstick whole-blood lactate measurement)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (non-lactate measurement)
Number of subjects: 59
Study: 21803780

Group type: EXPERIMENTAL
Intervention: Dental amalgam fillings
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dental amalgam fillings
Number of subjects: 0
Study: 19434420

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) group (n = 18) performed three times/week a static exercise on a vibration platform (6 sets of 1‐min with 1 min of rest, with a 12.6 Hz of frequency and an amplitude of 3 mm)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Walk-based program (WP) group (n = 18) performed three times/week a 60‐min of walk activity at 70‐75% of maximal heart rate
Number of subjects: 27
Study: 17299499

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g long-chain n-3 fatty acids per day from week 20 for groups 1 and 2; 6.3 g from week 33 for group 3)
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 968

Group type: COMPARATOR
Intervention: Control (olive oil capsules)
Number of subjects: 968
Study: 15384144

Group type: EXPERIMENTAL
Intervention: Nucleotide depletion primer extension assay for SNP determination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MALDI-TOFMS technique for SNP determination
Number of subjects: 0
Study: 11273850

Group type: EXPERIMENTAL
Intervention: 1 g American ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 g American ginseng
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 g American ginseng
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: American ginseng administered 40 min before glucose challenge
Number of subjects: 12
Study: 9340441

Group type: EXPERIMENTAL
Intervention: Nebulizer therapy (0.5 ml ‐ 125 micrograms ipratropium bromide and 250 micrograms phenoterol)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Aerosol therapy (40 micrograms ipratropium and 100 micrograms phenoterol)
Number of subjects: 34
Study: 1285936

Group type: EXPERIMENTAL
Intervention: 10 mg nitrendipine twice daily (titrated up to 30 mg twice daily during open label period)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide daily
Number of subjects: 32
Study: 3809304

Group type: EXPERIMENTAL
Intervention: Clomipramin, 50 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amitriptylin, 50 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desipramin, 50 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Imipramin, 50 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diazepam, 10 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbamazepin, 200 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haloperidol, 3 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clomipramin, 25 mg (intravenous)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28753136

Group type: EXPERIMENTAL
Intervention: Coach2Move
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 30442157

Group type: EXPERIMENTAL
Intervention: Facilitation interventions (two types)
Number of subjects: 16
Study: 26715229

Group type: COMPARATOR
Intervention: PCBT‐I (n = 81)
Number of subjects: 242

Group type: COMPARATOR
Intervention: VCBT‐I (n = 80)
Number of subjects: 242

Group type: COMPARATOR
Intervention: CTL (n = 81)
Number of subjects: 242
Study: 25117873

Group type: EXPERIMENTAL
Intervention: Eccentric training of the dominant limb with a dynamometer in eccentric mode at 60°/s, 3 times per week for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 18
Study: 21793769

Group type: EXPERIMENTAL
Intervention: Fixed low-dose oxytocin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard incremental low-dose oxytocin
Number of subjects: 116
Study: 20954779

Group type: EXPERIMENTAL
Intervention: Evidence-based leaflet plus five postcards facilitating recruitment and donor registration
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Five postcards alone
Number of subjects: 734

Group type: COMPARATOR
Intervention: No materials
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Postcards plus leaflet
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Postcards alone
Number of subjects: 734
Study: 17021740

Group type: COMPARATOR
Intervention: Ropivacaine 0.25%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% plus 50 mg magnesium
Number of subjects: 60
Study: 15723860

Group type: EXPERIMENTAL
Intervention: Simplified total-etch and self-etch adhesives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control three-step total-etch adhesive
Number of subjects: 0
Study: 11913290

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide strip system, used twice daily for 30 minutes (total of 56 contact hours over 8 weeks)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide tray system, used overnight (approximately 448 contact hours)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 106
Study: 9707740

Group type: EXPERIMENTAL
Intervention: Omeprazole; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 8551804

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with < or = 5% residual blasts at D15
Number of subjects: 437

Group type: COMPARATOR
Intervention: Induction chemotherapy with > 5% residual blasts at D15
Number of subjects: 437
Study: 2246174

Group type: EXPERIMENTAL
Intervention: Methacholine inhalation tests in normal subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methacholine inhalation tests in asthmatic subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day) and flurbiprofen (150 mg/day) pretreatment in normal subjects
Number of subjects: 24
Study: 6936982

Group type: EXPERIMENTAL
Intervention: treatment with a mixture of 7 grass pollen extracts (Allpyral)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: treatment with a cocksfoot pollen extract (Allpyral)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: treatment with a rye pollen extract (Allpyral)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: treatment with a mixture containing 50% rye pollen and 50% cocksfoot (Allpyral)
Number of subjects: 128

Group type: COMPARATOR
Intervention: control group without immunotherapy
Number of subjects: 128
Study: 31898177

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: No Desmopressin (Control)
Number of subjects: 202
Study: 30427055

Group type: EXPERIMENTAL
Intervention: Subscapularis-sparing total shoulder arthroplasty (SPARING)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard total shoulder arthroplasty (STANDARD)
Number of subjects: 70
Study: 28899951

Group type: EXPERIMENTAL
Intervention: anti-IL-12/23 (ustekinumab)
Number of subjects: 150
Study: 26324784

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Physicians' adherence
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 99
Study: 24020078

Group type: EXPERIMENTAL
Intervention: nCPAP combined with antireflux medicine (esomeprazole 40 mg/d and mosapride citrate 5 mg, 3 times a day, oral)
Number of subjects: 60

Group type: COMPARATOR
Intervention: nCPAP alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: nCPAP combined with antireflux medicine
Number of subjects: 60
Study: 21770847

Group type: EXPERIMENTAL
Intervention: Values writing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral writing task (control)
Number of subjects: 0
Study: 19645974

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine or bupivacaine (Treatment Group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (Placebo Group)
Number of subjects: 72
Study: 17302060

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) - glucosidorum tripterygll totorum and Yishen Juanbi Pill
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Western Medicine (WM) - non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs
Number of subjects: 356

Group type: COMPARATOR
Intervention: Control group (ineffective treatment)
Number of subjects: 356
Study: 15217308

Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol) 40 mg twice daily plus dietary counselling
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (dietary counselling only)
Number of subjects: 77
Study: 11216808

Group type: EXPERIMENTAL
Intervention: Azathioprine (4 mg/kg intraoperatively and 2.0 +/- 0.5 mg/kg once daily for 3 months)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no azathioprine)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 13
Study: 9773716

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) at 0.625 mg/day
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) at 2.5 mg daily (continuous MPA)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) at 10 mg on days 1-12 (cyclical MPA)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) at 200 mg on days 1-12 (cyclical)
Number of subjects: 788
Study: 7848884

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg (rescue infusion)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg, 10 mg, 20 mg, 40 mg (study I)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 217
Study: 3141867

Group type: EXPERIMENTAL
Intervention: Active allergen injection during treatment sessions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo injection during treatment sessions
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Neutralization subcutaneous treatment
Number of subjects: 33
Study: 29384754

Group type: EXPERIMENTAL
Intervention: Knocking-fingers (KF) technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-finger (TF) technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-thumb encircling hands (TT) technique
Number of subjects: 0
Study: 27624148

Group type: EXPERIMENTAL
Intervention: 1.5 mg of oral THC twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18